82 results about "Combined Vaccines" patented technology

The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. Specific embodiments relate to RNA betacoronavirus vaccines formulated in a lipid nanoparticle.

The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. Specific embodiments relate to RNA betacoronavirus vaccines formulated in a lipid nanoparticle.

The present disclosure relates to field of lyophilized / freeze-dried viral combination composition / formulation and methods for manufacturing and obtaining the composition comprising at least three live attenuated virus selected from a group of Coronavirus, Measles virus and Rubella virus; and stabilizers comprising of at least one carbohydrate, at least one amino acid and at least one hydrolyzed protein. The said lyophilized / freeze-dried viral combination composition / formulation is a vaccine composition that preserves the desired characteristics of each virus, including stability and immunogenicity. The composition can be safely administered subcutaneously as a combination vaccine composition such that the immunogenicity of each of the measles, rubella and SARS-CoV-2 is not inferior to that observed for each of the three viruses when administered as individual vaccines and is found to be equivalent or improved as compared to immunogenicity of SARS-CoV-2 vaccine given intranasally. The purification process is devoid of chromatography steps.

The present disclosure relates to the field of RNAs for the prevention or treatment of various infectious agents. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection, influenza infection and / or RSV infection and induction of effective coronavirus, influenza virus and / or RSV antigen-specific immune responses, such as antibodies and / or T cell responses. Specifically, in one embodiment, the disclosure relates to a method comprising administering to a subject (i) a bivalent RNA vaccine encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein), and (ii) a tetravalent RNA vaccine encoding a peptide or protein comprising an epitope of hemagglutinin (HA), the present invention relates to a method for inducing an immune response in a subject against a coronavirus S protein, in particular an S protein of SARS-CoV-2, and an influenza protein, in particular an HA protein of influenza A and B viruses.

The invention discloses a method for detecting the copy number of mRNA (messenger ribonucleic acid) of a novel crown RSV (respiratory syncytial virus) combined vaccine. A primer probe combination adopted by the detection method consists of primer pairs as shown in SEQ ID NO.2 and SEQ ID NO.3 and a probe as shown in SEQ ID NO.4, the 5'end of the probe is marked with a fluorescence reporter group, and the 3 'end of the probe is marked with a fluorescence quenching group. According to the detection method, correlation coefficients of equations between the Cq value and the template copy number are both larger than 0.99, amplification efficiency is both 90%-110%, and specificity and accuracy are good; the method can be used for quality control processes such as release detection in the combined vaccine development process and toxicological experiments, and has important significance and value for research and development and quality control of combined vaccines.

The present invention discloses a method for preparing a bivalent dysentery conjugate combination vaccine, which belongs to the technical field of biological product preparation. The vaccine includes two serotypes, 2a flexneri and sonnei. The O-specific polysaccharides of the two bacteria are covalently bound to a carrier protein according to their unique chemical structure through a corresponding chemical method to prepare a polysaccharide-protein conjugate stock solution. The polysaccharide-protein conjugate stock solution is then adsorbed with an aluminum adjuvant in an appropriate proportion to obtain a dysentery conjugate vaccine. The 2a flexneri dysentery polysaccharide is prepared as a conjugate by a reductive amine method, and the sonnei dysentery polysaccharide is prepared as a conjugate by a direct conjugation method with a spacer. In particular, the present invention no longer uses the highly toxic reagent cyanogen bromide and a high activation pH. The method is free of toxic reagents, has a mild reaction, is easy to control, and is conducive to future large-scale production. The dysentery conjugate vaccine prepared by the present invention is used for the immune prevention of infection with related serotypes of Shigella dysenteriae.

Provided are a primer-probe combination for real-time quantitative PCR, a related kit, and a method for using primers to measure the titers of measles, mumps and varicella virus pathogens. The method is applicable to clinical and laboratory detection, is fast and convenient, and has high sensitivity.

Provided is a liquid formulation of a six combined vaccine containing DPT-IPV-Hib-HBs, in which a HBs antigen is stably adsorbed and retained to an aluminum adjuvant, and PRP as a Hib antigen is stably coupled and retained to a carrier protein. A method for producing a stable liquid formulation of a six combined vaccine against diphtheria, pertussis, tetanus, polio, Haemophilus influenzae type b (Hib), and hepatitis B (HepB), the method comprising the following steps of: (1) mixing diphtheria toxoid (D) and tetanus toxoid (T) with an aluminum adjuvant to produce a DT adjuvant; (2) mixing a hepatitis B surface (HBs) antigen with the DT adjuvant obtained in step (1) to produce a DT-HBs adjuvant; (3) mixing a pertussis antigen (P) with the DT-HBs adjuvant obtained in step (2) to produce a DPT-HBs adjuvant; (4) mixing inactivated poliovirus (IPV) with the DPT-HBs adjuvant obtained in step (3) to produce a DPT-IPV-HBs adjuvant; (5) adding a succinate phosphate buffer to the DPT-IPV-HBs adjuvant obtained in step (4), and then adding PRP (PRP-T conjugate) as a Hib antigen to produce a mixture of DPT-IPV-Hib-HBs adjuvant and PRP-T conjugate; and (6) adjusting pH of the mixture of DPT-IPV-Hib-HBs adjuvant and PRP-T conjugate obtained in step (5) to 5.4 to 5.9.

The invention relates to a preparation method of a babesiella bovis vaccine, belongs to the technical field of vaccines, and particularly relates to a combined vaccine based on silver nanoparticles (AgNPs) and theileria bovis antigen, the vaccine comprises 10-50nm AgNPs, the surface of the AgNPs is modified with carboxyl, amino or PEG, and the AgNPs are used for covalently coupling RAP-1 protein or immunogenic fragments thereof and MSA-2 protein or B cell epitope peptide thereof, the RAP-1 protein comprises an amino acid sequence (nucleotide sequence is as shown in SEQ ID NO: 1), the MSA-2 protein comprises an amino acid sequence (nucleotide sequence is as shown in SEQ ID NO: 2), and the preparation method comprises the following steps: carrier construction, recombinant expression, protein purification and AgNPs coupling to form a silver nanoparticle antigen compound, and the silver nanoparticle antigen compound is coated with chitosan to prolong the in-vivo half-life period.

A solution has been discovered that provides a more effective Coronavirus vaccine. The solution is an mRNA vaccine encoding a SARS-CoV-2 nucleoprotein (N) (mRNA-N) in combination with an mRNA vaccine encoding SARS-CoV-2 spike protein(S) (mRNA-S). Chemically modified mRNA-N (pseudouridine) and / or chemically modified mRNA-S (pseudouridine) can be synthesized and packaged in lipid nanoparticles (LNP). In mouse and hamster models, it was shown that mRNA-N alone is immunogenic and can significantly diminish viral loads in the mouse lung after prime-boost intramuscular immunization. In addition, the combinatorial mRNA-N / mRNA-S vaccination induces substantially stronger protection against SARS-CoV-2 than vaccination with mRNA-S alone.

The invention relates to the technical field of vaccine preparation, in particular to a porcine Japanese encephalitis virus and porcine parvovirus VP2 protein bivalent vaccine as well as a preparation method and application thereof. According to the invention, the JEV-PPV VP2 combined vaccine is prepared by combining the JEV whole-virus inactivated vaccine with the VLP assembled by the expressed PPV VP2 protein, so that the organism can be induced to generate good cellular immunity and humoral immunity, the organism is protected from being damaged by PPV and JEV, and a certain basis and direction are provided for research on the aspect of combined use of vaccines in the future.

The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. Specific embodiments relate to RNA betacoronavirus vaccines formulated in a lipid nanoparticle.

The application discloses a novel group B meningococcal outer membrane protein bifunctional carrier, relates to the technical field of biopharmaceutical processes, and discloses a group B meningococcal outer membrane protein bifunctional carrier and application of the bifunctional carrier in a meningitis combined vaccine. The bifunctional carrier is human H factor binding protein fHbp, and comprises two kinds of recombinant proteins BA and BB, and the amino acid sequences of the two kinds of recombinin proteins are SEQ ID No. 62 and SEQ ID No. 63 respectively. The BA protein is coupled with group A capsule polysaccharide to form a group A combined vaccine, the BB protein is coupled with group C capsule polysaccharide to form a group C combined vaccine, and the two are mixed to form a group ABC triple vaccine. Each dose of the triple vaccine contains 40 μg of group A / C polysaccharide, 160 μg of BA / BB protein in total and 1.0 mg of aluminum adjuvant. The BA and BB proteins are expressed by E. coli, are broken by high-pressure homogenization, and are purified by anion exchange chromatography, and the purity is greater than or equal to 95%. The triple vaccine can simultaneously induce immune responses to groups A, B and C of meningitis, the serum bactericidal titer is greater than or equal to 1:32 after primary immunization, and the titer is maintained for more than 56 days after three immunizations.

The invention discloses a modular combined vaccine soluble microneedle patch based on a mechanical interlocking tenon-and-mortise structure as well as a preparation method and application of the modular combined vaccine soluble microneedle patch. According to the combined and spliced micro-needle vaccine patch designed by the invention, synchronous delivery of various vaccines is realized by virtue of a micro-needle technology through fragmented loading and mechanical interlocking'mortise and tenon 'structural design, mutual interference among different vaccines is reduced at the same time, efficient protection can be provided for groups needing multi-vaccine protection by virtue of one-time inoculation, the number of inoculants is reduced, and the immune procedure is simplified; vaccine hesitation is reduced, and inoculation rate is increased; meanwhile, the biosoluble material of the microneedle structure can quickly release antigens in the skin to stimulate immune cells to aggregate so as to enhance the immune effect; the micron-sized needle array (lt; 500 m) acts on the superficial layer of the skin, is painless and can be designed into a self-adhesive patch, so that the inoculation compliance is improved; single-dose inoculation can also reduce medical cost, is suitable for resource-deficient regions, improves accessibility and burdenability, and accelerates establishment of a population immune barrier.

Provided are a pneumococcal conjugate combined vaccine and a preparation method therefor. The combination comprises 26 different pneumococcal polysaccharide-protein conjugates, and the pneumococcal polysaccharide comprises a total of 26 serotypes, i.e., 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 24F, 33F and 35B. The carrier protein used by the conjugate is tetanus toxoid (TT). The polysaccharide is covalently linked to the TT by means of a cyano activation method so as to prepare a polysaccharide-protein conjugate stock solution, and the polysaccharide-protein conjugate stock solution is then adsorbed by an aluminum adjuvant in an appropriate proportion so as to obtain the pneumococcal conjugate vaccine. The pneumococcal polysaccharide used therein requires no degradation reaction, effectively protecting the antigenicity of the polysaccharide. Three consecutive batches of production of the conjugate stock solution and vaccine are performed, and the yield and each verification index of the conjugate are stable. The results of non-clinical safety evaluation research show that the vaccine has good safety and immunogenicity. The prepared pneumococcal conjugate vaccine is used for immunoprophylaxis of pneumococcal infection of relevant serotypes.

The present disclosure relates to combination RNA vaccines and uses thereof. The present disclosure also relates to conventional mRNA vaccines and self-replicating RNA vaccines for the treatment of diseases or conditions including respiratory syncytial virus (RSV).

The application discloses a competitive ELISA detection method for Hib polysaccharide in an aluminum-containing adjuvant vaccine, and specifically, the method comprises the following steps: enzyme label plate preparation: coating Hib stock solution or PRP derivative on an enzyme label plate to prepare an enzyme label plate required for ELISA reaction; aluminum adsorption Hib sample treatment: blocking aluminum adjuvant adsorbed Hib reference and aluminum adjuvant containing vaccine samples with BSA, respectively, and then diluting the aluminum adjuvant adsorbed Hib reference and aluminum adjuvant combined vaccine samples after blocking; ELISA detection: adding the diluted aluminum adjuvant adsorbed Hib reference and aluminum adjuvant containing vaccine samples into the enzyme label plate, respectively, and then adding Hib specific antibody, generating ELISA signals through enzyme label antibody catalysis of substrates, establishing a mathematical relationship between absorbance and Hib polysaccharide content, and quantitatively calculating the Hib polysaccharide content in the aluminum adjuvant containing vaccine sample.

The invention discloses a preparation method and application of a novel coronavirus and dengue virus combined vaccine, and belongs to the technical field of biology. The invention provides an SARS-COV-2 and DENV chimeric VRP vaccine and a DREP vaccine based on an SINV replicon. The vaccine can generate virus protein with immunogenicity in cells, can induce a mouse to generate an antibody aiming at SARS-CoV-2, and shows neutralizing activity on the SARS-CoV-2 virus and DENV virus at the same time. Compared with a mouse inoculated with a DREP vaccine, an immunization method inoculated with a VRP vaccine is simpler and more convenient, and generation of a higher-level antibody can be induced. The chimeric vaccine provided by the invention can protect human beings or mammals from being infected with novel coronavirus and dengue hemorrhagic fever, so that the novel coronavirus and dengue virus are effectively blocked from spreading and prevalence in people.

The invention relates to the field of biological medicine, and particularly discloses an RSV-influenza combined vaccine and application thereof. The RSV-influenza combined vaccine comprises a respiratory syncytial virus mRNA vaccine and an influenza vaccine, the respiratory syncytial virus mRNA vaccine also comprises lipid nanoparticles, and the mRNA is loaded in the lipid nanoparticles. The RSV-influenza combined vaccine is used for preventing infection of various respiratory viruses (RSV virus and influenza virus), and the LNP adjuvant of the RSV mRNA vaccine can greatly increase the immune response of the influenza vaccine and enhance the protection efficiency of the influenza vaccine in immunocompromised people.

To provide EBV ribonucleic acid vaccines as well as methods of using the vaccines and compositions comprising the vaccines.SOLUTION: Provided herein, in some embodiments, are Epstein-Barr virus (EBV) ribonucleic acid (RNA) (e.g., mRNA) vaccines (e.g., combination vaccines) that elicit potent neutralizing antibodies and robust T cell responses, inhibit the production of viral immunomodulatory factors, and / or prevent viral latency.SELECTED DRAWING: None

The present invention relates to a combination of a first vaccine comprising a non-replicating immunogen of porcine erysipelothrix sp. And a non-replicating immunogen of porcine parvovirus and a second vaccine comprising a non-replicating immunogen of leptospira sp. And the first vaccine and the second vaccine are jointly injected into corium layers of a first injection part and a second injection part of the pig at different points to prophylactically treat the pig so as to resist swine erysipelothrix erysipelas infection, porcine parvovirus infection and leptospirosis infection.

Disclosed in the present invention is a compound adjuvant combined vaccine, comprising an immunogenic composition and a compound adjuvant. The immunogenic composition comprises a pertussis antigen, a diphtheria antigen and a tetanus antigen; and the compound adjuvant is composed of an aluminum adjuvant and a TLR9 receptor agonist. Further disclosed in the present invention is a use of the compound adjuvant in the preparation of the compound adjuvant combined vaccine for preventing pertussis, diphtheria and tetanus in a subject.

To provide combination vaccines for swine.SOLUTION: Provided is a combination vaccine for protection against a pathogenic infection with porcine circo virus type 2 (PCV2) and Mycoplasma hyopneumoniae (Mhyo) comprising non-replicating immunogen of PCV2 and non-replicating immunogen of Mhyo. The vaccine is characterized in that it is an oil-in-water emulsion comprising squalane, vitamin E-acetate and silica. In another embodiment, the invention provides a combination vaccine for protection against a pathogenic infection with PCV2 and Mhyo by intradermal administration.SELECTED DRAWING: None

The present disclosure provides vaccine compositions comprising a plurality of different antigens. Also provided are nucleic acid vaccine compositions comprising one or more nucleic acids encoding a plurality of different antigens. The plurality of different antigens include a combination of influenza antigens. The vaccine compositions may be formulated as mRNA / LNP, recombinant proteins, virus-like particles (VLPs), or DNA for delivery. Methods of preventing influenza infection and methods of inducing an immune response are also disclosed.

The invention provides a quintuplet inactivated vaccine for sheep multiple lung rot disease and a preparation method thereof, and belongs to the technical field of multi-combined vaccines. According to the invention, five pathogens are combined in one vaccine, so that animals can generate effective antibodies aiming at multiple pathogens while one vaccine is used for immunization, the effect of preventing multiple diseases by one injection is achieved, and the prevention and control effect of the lung rot disease is improved. Meanwhile, the quintuplet inactivated vaccine can avoid frequent capture of activities of the sheep due to injection of various monovalent vaccines, reduces animal stress caused by driving and fixation, reduces the working intensity of immunization personnel, has very important clinical application value and wide market prospect, and can generate huge social and economic benefits.

The invention provides a combined vaccine based on Th1 / Th2 immune dynamic equilibrium as well as a preparation method and application of the combined vaccine. Subcutaneous delivery of interleukin 12 (IL12) and antigen (such as ovalbumin OVA) mRNA is adopted in the early stage of tumor occurrence, so that specific antigen recognition and T cell immune response of an organism are activated; when immune response enters a function decline stage, the tumor microenvironment is regulated through intratumor delivery of interleukin 4 (IL4) mRNA, the metabolic activity of T cells is maintained, and the depletion of the T cells is delayed. Through space (subcutaneous / intra-tumor) and time (early stage / middle stage) separated delivery of different immune factors, 'start-steady state maintenance 'type immune stylization regulation and control are realized, antigen-specific CTL reaction and persistent anti-tumor effect are remarkably enhanced, and the problem of immune bias caused by independent use of the antigen-specific CTL reaction and the persistent anti-tumor effect is solved.

The invention relates to the field of preparation of poultry vaccines, in particular to a preparation method of a chicken newcastle disease and avian influenza combined vaccine, which comprises the following steps: respectively inoculating susceptible chick embryos with Newcastle disease virus, infectious bronchitis virus and avian influenza virus, and harvesting infected chick embryo liquid to obtain first virus liquid, second virus liquid and third virus liquid; inoculating the susceptible duck embryo with the egg drop syndrome virus, and harvesting infected duck embryo liquid to obtain a fourth antigen; and concentrating the harvested first virus liquid, second virus liquid, third virus liquid and fourth antigen, inactivating, and mixing and emulsifying with an adjuvant. The vaccine prepared by the invention does not generate any adverse reaction to chickens, is high in experimental safety, can induce high-level neutralizing antibodies in immunized chickens, and can effectively reduce the incidence of Newcastle disease virus, infectious bronchitis virus, egg drop syndrome and avian influenza.

The present invention relates to a vaccine, especially a combination vaccine providing at least a first and a second antigenic function, the combination vaccine comprising at least one RNA encoding at least one or more proteins or fragments, variants or derivatives of proteins awarding antigenic function, wherein the first antigenic function being a Fusion (F) protein or a fragment, variant or derivative of a Fusion (F) protein derived from the virus family Paramyxoviridae and the second antigenic function being an Hemagglutinin (HA) protein or a fragment, variant or derivative of an Hemagglutinin (HA) protein derived from the virus family Orthomyxoviridae. Furthermore, the present invention is directed to a kit or kit of parts comprising the components of said combination vaccine and to said combination vaccine for use in a method of prophylactic or therapeutic treatment of diseases, particularly in the prevention or treatment of infectious diseases like RSV and influenza.

The application discloses an influenza virus universal and coronavirus combined polypeptide and application of a vaccine thereof, and belongs to the technical field of vaccine preparation. The vaccine is an artificial synthetic vaccine, has the characteristics of easy preparation, small toxicity, low cost, high titer, broad spectrum and conservation, and solves the complicated process of obtaining a vaccine by amplification transformation in the prior art, and improves the preparation efficiency and application efficiency. A combined polypeptide vaccine component having immunoprotection for multiple subtypes of influenza viruses and coronaviruses is designed for influenza viruses and novel coronaviruses, and Montanide ISA51 is used as an adjuvant. After mice immunized with the vaccine are infected with influenza viruses by nose dropping, it is shown that the vaccine immunization has a protective effect on mice adapted strains of influenza A H1N1 and H7N9 viruses, the combined vaccine composed of the screened six polypeptides has a protective effect on multiple influenza viruses, and has the potential to resist coronaviruses.

The invention provides an mRNA (messenger Ribonucleic Acid) molecule aiming at a coronavirus SARS-CoV-2 and / or an influenza virus, an mRNA vaccine containing the molecule and application of the mRNA vaccine. According to the combined vaccine, mRNA molecules respectively aim at Spike protein of an SARS-CoV-2 strain subjected to stable mutation or hemagglutinin protein of an influenza strain, optimized mRNA sequences can play an effective immune role, and the combined vaccine provided by the invention can activate specific immune response of an organism immune system aiming at various virus antigens; the immunoreaction can be synergistically enhanced through combined stimulation of various virus antigens.